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Long-term follow-up of type II endoleak
embolization reveals the need for close
surveillance
Timur P. Sarac, MD, Connor Gibbons, Lina Vargas, MD, Jane Liu, MD, Sunita Srivastava, MD,
James Bena, MS, Tara Mastracci, MD, Vikram S. Kashyap, MD, and Daniel Clair, MD, Cleveland, Ohio
Objective: Aneurysm growth after endovascular aneurysm repair (EVAR) in patients with type II endoleak is associated
with adverse outcomes. This study evaluated the long-term success of embolization of type II endoleaks in preventing
aneurysm sac growth.
Methods:We retrospectively reviewed outcomes of patients who underwent infrarenal EVAR who were treated for a type
II endoleak between 2000 and 2008. Computed tomography scans were evaluated for aneurysm sac growth or shrinkage
from the time of treatment of the endoleak. The embolization material used, graft type, target vessel embolized, and
comorbidities were evaluated for their association with sac growth or shrinkage.
Results: Ninety-five patients underwent 140 embolization procedures. The mean time from EVAR to embolization was
26.1  22.2 months, and the average increase in size of the aneurysm sac from EVAR to treatment was 0.7  0.5 cm.
Patients underwent an average of 1.6  0.8 embolization procedures after EVAR. Thirteen patients underwent initial
simultaneous embolization of two targets. Embolization was with glue (61%), coils (29%), glue and coils (7%), and
Gelfoam (3%; Pfizer Inc, New York, NY). No abdominal aortic aneurysms (AAA) ruptured. Eight patients (8.4%)
underwent graft explant and open repair; 19 (20%) required two or more embolization procedures. There was no
difference in the target vessel treated or the treatment used in halting sac expansion (>5 mm). Coil embolization alone
resulted in more second procedures. The 5-year cumulative survival was 65% (95% confidence interval [CI], 52%-77%),
freedom from explant was 89% (95% CI, 81%-97%), freedom from second embolization was 76% (95% CI, 66%-86%), and
freedom from sac expansion >5 mm was 44% (95% CI 30%-50%). Univariable analysis identified continued tobacco use
(hazard ratio [HR], 2.30; 95% CI, 1.02-5.13; P .04) was associated with continued sac expansion, and hyperlipidemia
(HR, 9.64; 95% CI, 2.22-41.86) was associated with patients requiring a second embolization procedure.
Conclusions: Embolization of type II endoleaks is successful early in preventing aneurysm sac growth and rupture after
EVAR. However, a significant number of patients require more than one procedure, and at 5 years, many patients who
underwent embolization of a type II endoleak continued to experience sac growth. Patients with hyperlipidemia who
undergo coil embolization are more likely to require a second embolization procedure, and patients who smoke have a
higher likelihood of AAA sac expansion after embolization. Continued long-term surveillance is necessary in this cohort
of patients. ( J Vasc Surg 2012;55:33-40.)
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wType II endoleaks occur after endovascular aneurysm
repair (EVAR) due to retrograde flow from aortic periph-
eral vessels into the abdominal aortic aneurysm (AAA) sac
and occur in10% to 30% of patients. They were originally
described by White et al,1 and their importance was docu-
mented in an international forum of experts.2 Most type II
endoleaks are innocuous, but some are associated with
aneurysm sac enlargement and require a secondary inter-
vention.3 Patients whose aneurysm sac continues to grow
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doi:10.1016/j.jvs.2011.07.092equire treatment by embolization through the transarte-
ial route,4 direct sac puncture,5 endoscopic ligation of the
umbar or mesenteric arteries,6 aneurysm sac plication,7,8
r in the most severe circumstance, surgical explant.9-11
Although the significance of asymptomatic type II en-
oleak has been debated,12-15 persistent type II endoleaks
hat are associated with an increase in aneurysm sac diam-
ter have an increased incidence of adverse outcomes.16,17
any potential strategies exist to treat type II endoleaks,
ut the optimum treatment and long-term success for
reating type II endoleaks is not known. This study sought
o evaluate the specific vessel treated, type of treatment, and
ong-term success of embolization of type II endoleaks in
AA patients. We also analyzed which factors might be
ssociated with continued AAA sac growth after type II
ndoleak treatment.
ATERIALS AND METHODS
This study was approved by the Institutional Review
oard. We conducted a retrospective review of all patients
ho underwent embolization of a type II endoleak for
neurysm sac growth between November 1999 and April
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January 201234 Sarac et al2009. Type II endoleak embolization was done at the
discretion of the attending surgeon, but in general, treat-
ment was initiated if the patient had a persistent type II
endoleak and the aneurysm grew 5 mm after EVAR. Of
the 95 patients treated, two-thirds had undergone the
original EVAR at our institution, and one-third were re-
ferred specifically for endoleak treatment. The study did
not include vessels embolized at the time of graft implant.
Specific treatments were individualized to patient anat-
omy and done at the judgment of the attending surgeon. In
general, type II inferior mesenteric artery (IMA) endoleaks
were treated by accessing the middle colic artery through
the superior mesenteric artery and retrograde to access the
IMA through the arc of Riolan or the marginal artery.18
Lumbar endoleaks were most commonly accessed through
retrograde cannulation of the iliolumbar arteries from the
hypogastric arteries,19 and direct sac puncture was done by
placing the patient in the lateral position and using
fluoroscopic guidance to cannulate the sac with a spinal
needle, usually followed by glue embolization.20
Computed tomography (CT) scans were done before
and after the procedure by a three-phase CT scan and on
single or multidetector CT machines (Somatom Plus 4,
Volume Zoom, Sensation 16, and Senation 64, Siemens,
Erlangen, Germany). Before 2004 (the year of approval of
Zenith Flex endograft), a CT scan was customary before
discharge and at 1 month, 6 months, and yearly thereafter
if there was no aneurysm growth. After 2004, CT scans
were obtained less frequently and were the limited to 1
month and yearly thereafter, if no adverse findings were
identified. More frequent CT scans were obtained if there
was a new endoleak detected, significant migration, or
enlargement of the aneurysm sac. All preoperative and
postoperative CT scans were independently re-reviewed
and compared with the initial radiology and surgeon read-
ings, and aneurysm sac size and endoleak was recorded.
Maximum aneurysm luminal size was determined by the
shortest diagonal of the cross-sectional CT image, and the
shortest and largest measurements at that point were re-
corded.
Patient hospital, office, and CT scan records were re-
viewed, and demographics are listed in Table I. Dyslipide-
mia and tobacco use were taken from the patient’s history.
Levels of serum cholesterol, triglycerides, and nicotine were
not directly measured as part of this study. Operative notes
were reviewed for the target vessel embolized (IMA, hypo-
gastric artery, lumbar artery), direct aortic sac puncture,
endograft placed, and the embolization material used, in-
cluding coils (Cook Inc, Bloomington Ind); N-butyl cya-
noacrylate (Cordis Neurovascular, Miami Lakes, Fla), bo-
vine thrombin (King Pharmaceuticals, Bristol, Tenn), and
Gelfoam (Pfizer Inc, New York, NY).
Outcomes measures and statistical analysis. The
outcomemeasures analyzed included cumulative mortality,
and freedom from sac growth, second embolization proce-
dure, and graft explant. Deaths were documented from
office and hospital records and the Social Security Death
Index Database. Freedom from aneurysm growth was de- tned as sac growth 5 mm on the concomitant minor or
ajor axis at the largest area of the minor axis. Correlations
etween outcome measures and variables included comor-
idities, vessel treated, material used in treatment, access
ite, and specific stent graft. Categoric factors were summa-
ized using frequencies and percentages and continuous
easures were described using means, standard deviations,
nd percentiles of interest. To estimate survival and free-
om from sac expansion, explant, and second repair,
aplan-Meier estimation was used, and 95% confidence
ntervals (CIs) for these estimates were created. P values
rom log-rank tests were used to compare these measures
cross demographic and clinical factors. Hazard ratios
HRs) from Cox proportional hazards models are pre-
ented to quantify risk differences across groups.
Multivariable analysis was not preformed due to the
imited number of significant variables. Correlations be-
ween major and minor axis measurements were calculated
sing Bland-Altman methods.21,22 Analysis was performed
sing SAS 9.1 software (SAS Institute, Cary, NC) andR 2.8
oftware (Vienna, Austria).
ESULTS
The following stent grafts were used to treat 809
oninvestigational study aneurysms: Zenith (Cook Inc),
neuRx and Talent (Medtronic, Minneapolis, Mn.), An-
ure (Guidant, Indianapolis, Ind), and Excluder (W.L.
ore and Associates, Flagstaff, Ariz). Eight patients under-
ent endograft placement outside the United States, and
able I. Demographics
ariable No. (%)
ex
Female 12 (12.6)
Male 83 (87.4)
oronary artery disease
No 38 (40)
Yes 57 (60)
iabetes mellitus
No 75 (79)
Yes 20 (21.1)
enal insufficiency
No 73 (76.8)
Yes 22 (23.2)
hronic obstructive pulmonary disease
No 74 (77.9)
Yes 21 (22.1)
ypertension
No 20 (21.1)
Yes 75 (79)
yperlipidemia
No 47 (49.5)
Yes 48 (50.5)
eripheral vascular disease
No 76 (80)
Yes 19 (20)
obacco
No 80 (84.2)
Yes 15 (15.8)hese included Anaconda and Talent endografts (listed as
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Volume 55, Number 1 Sarac et al 35“other”). Ninety-five patients (87% men, 13% women)
underwent 140 embolizations. Patient demographics are
listed in Table I. Comorbidities included hypertension,
79%; coronary artery disease, 60%; and smoking, 16%. The
median age was 77 years (95% CI 73-83 years). The mean
time from EVAR to embolization of the type II endoleak
was 26.1  22.2 months, and the average sac enlargement
measured at our institution from the time of our initial
measurement was 0.7  0.5 cm.
Patients underwent an average of 1.6  0.8 emboliza-
tion procedures, with 19 patients (20%) requiring more
than one embolization procedure, and 13 patients under-
going simultaneous embolization of two targets. The dis-
tribution of vessels embolized at the first and subsequent
treatments are 37% and 38% inferior mesenteric artery
(IMA), 38% and 38% lumbar, 11% and 9% proximal hypo-
gastric, 11% and 14% aneurysm sac, and 3% and 2% other.
Glue was used in 61% of the embolizations, followed by
coils in 29%, glue and coils in 7%, and Gelfoam in 3%. CT
scan measurements were highly correlated between differ-
ent observers, along with largest diameter at the major and
minor axis (P  .001).
The in-hospital/30-day complication rate per proce-
dure was 8.6%, which is similar to what we have previously
have reported.23 The complications were two cardiac (one
myocardial infarction and one atrial fibrillation), two mes-
enteric ischemia (superior mesenteric artery access for IMA
embolization), and one patient each with pseudoaneurysm,
renal perforation, aspiration pneumonia, multisystem or-
gan failure from bowel ischemia, catheter sepsis, lumbar
plexopathy (from excess glue spilling into other lumbar
vessels), and severe debilitating acute claudication. No
AAA ruptured.
The cumulative survival was 92.4% at 1 year and 64.5%
at 5 years. Univariable factors associated with survival are
listed in Table II. As expected, those with coronary artery
disease and diabetes had greater mortality rates. Those who
received an Ancure graft also had a higher mortality rate,
but the numbers were too small to make a meaningful
conclusion. Freedom from explant, freedom from second
embolization procedure, and freedom from sac growth are
shown in the Fig. At 1 year, freedom from explant was
100%, freedom from the second embolization procedure
was 84.9%, and freedom from AAA sac growth was 81.5%.
However, when these patients were monitored out to 5
years, there was continued decline in success of the embo-
lization procedure: freedom from explant decreased to
88.8%, freedom from second embolization procedure de-
creased to 75.8%, and freedom from sac growth 5 mm
decreased to 43.7%. Grafts were explanted in nine patients,
with average size at explant of 6.6  7.2 cm, with no
perioperative deaths.
The 5-year univariable analyses of comorbidities asso-
ciated with the three outcome measures analyzed are listed
in Table III. No single variable was associated with a greater
likelihood of graft explant. However, there was a higher risk
of aneurysm sac expansion with tobacco (HR, 2.30; 95%
CI, 1.02-5.13; P  .04). Hyperlipidemia was the only sariable that was associated with a greater risk of patients
equiring a second embolization procedure (HR, 9.64;
5% CI, 2.22-41.86).
The 5-year univariable analysis of different operative
actors associated with the three outcome measures are
isted in Table IV. The Zenith stent graft was less likely to
e explanted than the other grafts (97%; 95% CI, 91%-
00%; P .003) and had a lower incidence of sac expansion
5 mm at 5 years, but this did not reach statistical signifi-
ance. Although more IMA and lumbar arteries were em-
olized than direct sac puncture, proximal hypogastric
rtery, and lumbar arteries, no single vessel embolized
ffered better protection against explant, second interven-
ion, or sac growth. Embolization was performed more
requently with glue than with coils, combination glue and
oils, and Gelfoam. Although there was no difference in
aterial used in preventing sac expansion, those who un-
erwent only coil embolization were more likely to require
second intervention (51%; 95% CI, 34%-76%; P  .006).
here was no difference in success when access sites were
ompared. Finally, those who required more than one
mbolization procedure were more likely to require subse-
uent embolization procedures (P  .001).
ISCUSSION
EVAR is widely accepted as the standard of care for
outine repair of AAAs with appropriate anatomy. The
resence of endoleaks is one downfall of the procedure, and
he cost of treating and monitoring these poses significant
hallenges to the health care system. It is generally accepted
hat treating type I and III endoleaks is mandatory to
epressurize the sac, but treating type II, IV, and V en-
oleaks depends on whether symptoms develop or the AAA
ac continues to expand. Type IV endoleaks are generally
hought to resolve spontaneously, and type V endoleaks
tiology remains controversial. However, the decision to
reat a type II endoleak depends on whether there is an
ncrease in aneurysm sac size, generally agreed to be signif-
cant if it is 5 mm. Some have advocated treating all type
I endoleaks that have not spontaneously resolved by 6
onths,24 whereas others advocate selective therapy.15
ones et al16 documented that patients with a persistent
ype II endoleak 6 months have also been noted to have
dverse outcomes. Axelrod et al25 advocated selective pre-
perative embolization of a large IMA, but the value of this
as never verified or adopted on a large scale.
Given the significance of this debate, we sought to
nalyze our outcomes and long-term success of treating
ype II endoleaks and found the success rate in preventing
AA sac growth was quite good at 1 year. However, after
onitoring these patients out to 5 years, our success rate
iminished. After 5 years, 20% of the patients required a
econd procedure, 37.9% continued to have AAA sac
rowth, and 8.4% required explant and open repair. This
ends support to the complexity and multifactorial etiol-
gy of type II endoleaks, as originally described by Solis
t al,26 and likely in these patients, there are multiple
ources of flow into the AAA sac. Early success in treating
l
i
a
, haz
JOURNAL OF VASCULAR SURGERY
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ferent procedures, including coil or foreign body embo-
lization to obstruct the inflow vessel,27 branch vessel or
Table II. Univariable comparison of factors associated wit
Variable No.
Event perc
3 years
Overall 94 79 (70-88)
Sex
Female 12 73 (51-100)
Male 82 80 (70-90)
Coronary artery disease
No 38 87 (75-100)
Yes 56 74 (62-87)
Diabetes mellitus
No 74 81 (72-92)
Yes 20 68 (50-93)
Renal insufficiency
No 73 78 (68-89)
Yes 21 83 (67-100)
COPD
No 74 79 (69-90)
Yes 20 78 (61-100)
Hypertension
No 20 71 (52-96)
Yes 74 81 (71-91)
Hyperlipidemia
No 47 74 (61-89)
Yes 47 83 (72-97)
Peripheral vascular disease
No 75 77 (67-88)
Yes 19 86 (69-100)
Tobacco
No 80 79 (70-90)
Yes 14 77 (57-100)
Target
Hypogastric 11 80 (58-100)
IMA  lumbar 11 81 (60-100)
IMA only 31 68 (52-89)
Lumbar only 28 84 (71-100)
Others 3 100 (100-100)
Sac puncture 10 90 (73-100)
Material
Coil only 28 74 (58-93)
Gelfoam 3 67 (30-100)
Glue  coil 6 80 (52-100)
Glue only 57 83 (72-95)
Device
Zenith 40 83 (71-96)
Aneurx 29 82 (68-98)
Excluder 6 100 (100-100)
Talent 3 50 (13-100)
Ancure 3 NA
Other 8 62 (37-100)
Interventions, No.
1 55 77 (66-90)
2 23 78 (61-100)
3 13 92 (79-100)
4 3 50 (13-100)
Access
Brachial 13 82 (63-100)
Femoral 71 77 (67-88)
Flank 10 90 (73-100)
CI, Confidence interval; COPD, chronic obstructive pulmonary disease; HRAAA sac glue occlusion, or both, and intrasac vessel pigation with sac plication. However, none of these stud-
es assessed the patients 2 years after initial treatment,
nd no study compared the outcomes of each of these
erall survival
e (95% CI)
HR (95% CI) Overall P5 years
65 (53-79) NA NA
73 (51-100) 1.00 .71
64 (51-79) 0.82 (0.28-2.35)
76 (61-96) 1.00 .063
58 (43-77) 2.11 (0.94-4.74)
69 (56-85) 1.00 .042
49 (28-85) 2.17 (1.01-4.68)
67 (55-82) 1.00 .75
55 (30-100) 0.86 (0.33-2.24)
66 (53-82) 1.00 .18
61 (40-93) 1.68 (0.78-3.60)
51 (29-89) 1.00 .81
68 (56-84) 0.90 (0.38-2.11)
58 (44-78) 1.00 .19
71 (55-93) 0.61 (0.29-1.29)
62 (49-78) 1.00 .26
73 (51-100) 0.55 (0.19-1.57)
66 (53-81) 1.00 .58
58 (31-100) 1.31 (0.50-3.43)
66 (41-100) 1.00 .67
81 (60-100) 0.91 (0.20-4.10)
61 (43-86) 1.54 (0.49-4.78)
66 (45-96) 0.73 (0.20-2.62)
NA 2.11 (0.23-19.49)
60 (26-100) 1.51 (0.37-6.07)
61 (44-83) 1.00 .44
33 (7-100) 2.15 (0.613-7.51)
NA 0.69 (0.087-5.51)
74 (59-91) 0.76 (0.341-1.68)
69 (53-89) 1.00 .052
64 (43-94) 1.66 (0.71-3.88)
100 (100-100) 0.60 (0.12-2.84)
NA 3.65 (0.79-16.83)
NA 7.17 (1.50-34.29)
62 (37-100) 1.69 (0.47-6.14)
69 (55-86) 1.00 .97
56 (33-95) 1.12 (0.46-2.71)
68 (43-100) 1.16 (0.45-2.99)
NA 1.49 (0.19-11.51)
62 (33-100) 1.00 .79
65 (53-81) 0.84 (0.29-2.45)
60 (26-100) 1.19 (0.29-4.81)
ard ratio; IMA, inferior mesenteric artery; NA, not applicable.h ov
entagrocedures in long-term follow-up. Future develop-
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Volume 55, Number 1 Sarac et al 37ments and research needs be directed to designing stent
graft systems that obviate the need for management of
this problem.
Several different therapeutic modalities have been
reported to be effective in treating type II endoleaks, and
which treatment to use depends on patient anatomy and
the endoleak source. One goal of this study was to
examine whether one treatment and which vessel treated
offered better long-term success. Patients who under-
went coil embolization only were more likely to require
another intervention; however, they did not have a
Fig. Kaplan-Meier curves show freedom from event. No
growth 10% after 3 years.
Table III. Freedom from event percentage and 95% confi
Variable Explant HR (95% CI) P
Sac size 
mm
Male sex 86 (78-96) NA .29 45 (33-63
CAD 84 (73-98) 2.39 (0.48-11.90) .27 48 (33-70
Diabetes
mellitus
100 (100-100) NA .14 62 (37-10
RI 80 (57-100) 1.41 (0.28-6.98) .68 46 (24-88
COPD 100 (100-100) NA .12 42 (23-76
Hypertension 85 (75-96) NA .13 44 (31-62
Hypertension 82 (69-99) 1.66 (0.39-6.97) .49 40 (25-64
PVD 93 (82-100) 0.52 (0.064-4.26) .54 61 (41-92
Tobacco 100 (100-100) NA .23 32 (11-88
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary disea
aA significant association for the outcome listed was found with this factor.greater rate of sac growth or higher explant rate. In these aatients, the second intervention probably completed
he treatment; hence, there was no increased sac growth
r explant rate. Although the inferior results of coil-only
mbolization compared with other modes has not been
reviously reported in the literature, it has been docu-
ented by the group from Massachusetts General (un-
ublished personal communication from Christopher
wolek, MD). The reason for this is speculative but gives
redence to treating as many endoleak sources as possi-
le, including inflow, outflow, and the aneurysm sac
tself. The success likely is the result of a combination of
t the standard error (vertical lines) for freedom from sac
e interval (CI) and presence of comorbidity at 5 years
HR (95% CI) P
2nd
intervention HR (95% CI) P
.11 (0.39-3.18) .84 74 (64-86) 2.79 (0.37-20.90) .30
.00 (0.51-1.95) .99 73 (60-88) 1.13 (0.45-2.88) .79
.65 (0.25-1.69) .37 62 (41-92) 2.31 (0.87-6.08) .082
.03 (0.48-2.22) .94 54 (29-100) 2.03 (0.77-5.38) .14
.60 (0.77-3.33) .21 78 (61-100) 1.02 (0.34-3.08) .97
.18 (0.45-3.06) .74 72 (61-85) 2.50 (0.58-10.85) .20
.19 (0.61-2.34) .60 57 (43-77) 9.64 (2.22-41.86)a .001
.68 (0.29-1.56) .36 84 (69-100) 0.71 (0.21-2.45) .59
.30 (1.03-5.13)a .036 85 (67-100) 0.65 (0.15-281) .56
R, hazard ratio; PVD, peripheral vascular disease; RI, renal insufficiency.te thadenc
5
) 1
) 1
0) 0
) 1
) 1
) 1
) 1
) 0
)a 2
se; Hll of the above.
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January 201238 Sarac et alAlthough more expensive, glue may better because its
liquid properties allow it to disperse beyond the original
target vessel. We used glue more frequently than other
materials, but certain circumstances, such as a small AAA
sac, short IMA, and abundant lumbar collateral network,
may be a relative contraindication to glue use due to
occlusion from spill beyond the targeted vessel. We saw this
occur in two patients, who presented with colonic ischemia,
and one patient with lumbar plexopathy. Although techni-
cal considerations may have played a role, proper patient
and material selection remains an important anatomic con-
sideration.
No one specific culprit vessel treated afforded a better
success at long-term management of the type II endoleak.
This is not surprising, because not all endoleaks are the
same. Some have both inflow and outflow vessels, and
others appear to act more like a pseudoaneurysm, with flow
specific to the sac from one feeding vessel. In addition, the
“nondescript” type V endoleaks have not yet been fully
characterized and may play a role in these patients.
An interesting finding was that patients with hyperlip-
idemia required an increased number of interventions. It is
not possible to ascertain if the specific vessels treated in
these patients had significant atherosclerosis, which might
have contributed to accessing the source of endoleak.
However, hyperlipidemia and atherosclerosis have a well-
Table IV. Operative variable and freedom from event per
Variable Explant H
Target
Hypogastric 91 (75-100)
IMA  lumbar 100 (100-100)
IMA only 85 (68-100) 0.94
Lumbar only 87 (75-100) 1.20
Others NA
Sac puncture 67 (38-100) 3.20
Material
Coil only 81 (65-100)
Gelfoam 100 (100-100)
Glue  coil NA
Glue only 91 (82-100) 0.57
Device
Zenitha 97 (91-100)a
AneuRx 89 (75-100) 3.80
Excluder 80 (52-100) 7.80
Talent NA 35.0
Ancure NA
Other 69 (40-100) 10.0
Interventions, No.
1 100 (100-100)
2 96 (88-100)
3 39 (17-90)
4 NA
Access
Brachial 75 (43-100)
Femoral 91 (84-99) 0.86
Flank 67 (38-100) 3.26
HR, Hazard ratio; IMA, inferior mesenteric artery; NA, not applicable.
aA significant association with the outcome listed was found for this factor.known association with AAA formation.28 Unfortunately, mhe documentation of statin use and success of therapy was
nsufficient to make meaningful conclusions about whether
his had an effect in therapy or on the AAA sac wall. Also,
e did not directly measure cholesterol or triglyceride
evels. Tobacco use, the other risk factor, was associated
ith an increased risk of AAA sac expansion after treatment.
ronenwett et al29 were the first to document the effects of
obacco on untreated AAA growth. We found that active
mokers had an increased risk of AAA sac expansion after
reatment, but we did not directly measure nicotine levels.
he pathophysiologic mechanisms of this observation have
et to be elucidated, but active counseling and aggressive
ttempts at tobacco cessation should continue to be pro-
oted.
Those who received a Zenith graft were less likely to
ndergo a second embolization procedure and explant.
uriel et al30 previously reported differences in initial rates
f type II endoleaks by device. However, the differences
isappeared when these patients were analyzed out to 4
ears in a conglomerate study.31 Another study reported
he Zenith stent graft had a higher rate of sac shrinkage
ompared with the first-generation Excluder and the An-
ure grafts; however, neither the first-generation Excluder
or the Ancure are still in use.32 The reasons for our results
re unclear; however, these patients did not have a different
ate of sac growth, and the small number of patients may
ge and 95% confidence interval (CI) at 5 years
5% CI) P Sac expansion 5 mm
00 .53 50 (25-100)
A 75 (43-100)
9-10.40) 39 (22-69)
3-11.65) 55 (36-85)
A NA
9-35.87) 32 (7-100)
00 .65 49 (32-75)
A 50 (13-100)
A NA
4-2.28) 40 (24-67)
00 .003a 36 (21-62)
4-42.2) 57 (35-95)
8-124.2) 67 (38-100)
7-388) NA
A NA
1-110) 66 (35-100)
00 NA 78 (65-95)
A 21 (8-57)
A 21 (6-71)
A NA
00 .23 NA
0-7.35) 50 (37-68)
9-36.02) 32 (7-100)centa
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effect of each material has been identified.
The continued growth of the AAA sac in a significant
number of patients treated during long-term follow-up
began to appear at 1 year after treatment and then stabilized
thereafter. Although the stabilization was likely related to
the second embolization procedure, the embolization pro-
cedures are not innocuous: the overall complication rate
was 8.6%. Bequemin et al33 reported the European Collab-
orators on Stent-Graft Techniques for Aortic Aneurysm
Repair (EUROSTAR) experience with secondary interven-
tions and documented a higher incidence of conversion in
those undergoing a secondary procedure but not a higher
incidence of rupture. We found similar results for treating
type II endoleaks. The survival rates in this study were 92%
at 1 year and 64% at 5 years, which are similar to our overall
survival rates previously reported.30
This study does have limitations: it is retrospective in
nature and does not have an equal number of patients in
each group. Technical considerations were surgeon-specific
and not standardized. Also, the small number of patients
may have overlooked a type II error when analyzing specific
treatments, and given the small number of events, the
statistical association of hyperlipidemia and tobacco use
may be a type II error. Given the small number of events,
proportional modeling is less likely to identify relationships
Table IV. Continued
HR (95% CI) P 2nd
1.00 .48 55
0.55 (0.097-3.08) 100
1.57 (0.506-4.86) 69
1.70 (0.532-5.46) 76
3.42 (0.618-18.87)
1.66 (0.406-6.78) 83
1.00 .97 51
1.28 (0.28-5.98) 100
1.15 (0.14-9.24)
1.17 (0.57-2.38) 86
1.00 .21 81
0.63 (0.26-1.51) 75
0.75 (0.22-2.58) 67
2.29 (0.67-7.86)
2.86 (0.65-12.6)
0.58 (0.13-2.54) 75
1.00 .001 100
5.19 (2.08-12.93) 58
3.77 (1.36-10.43)
20.51 (4.92-85.44)
1.00 .47 61
0.58 (0.24-1.43) 76
0.76 (0.21-2.76) 83to events. With regard to the aneurysm measurements, weould not measure aneurysm sac volume, which might have
iven a more accurate evaluation of each therapy. Another
seful measure might have been the size of the feeding
essel and flow in relation to the success of therapy.
ONCLUSIONS
We found that in most patients who have aneurysm sac
rowth due to a persistent type II endoleak, secondary
ntervention is successful early in reducing the risk of fur-
her sac growth. However, a significant number of patients
ontinue to have late AAA expansion after embolization
nd require subsequent interventions. Coil embolization
lone may not be the best method for long-term success.
n the basis of the data from this report, we are more likely
o use glue embolization of type II endoleaks as our first
hoice of therapy. We reserve using coils for large vessels
nd those with short necks, where spilling of glue may be
azardous. Close surveillance of these patients is warranted,
nd sac plication with feeder ligation or explant may be
ecessary if the embolization is unsuccessful. Further inno-
ation in the next generation of endografts should be
irected at eliminating type II endoleaks completely.
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